Klaus R. Dr Veitinger, Director at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 500 shares at $261.17 ($131K) on 2015-08-03, disclosed to the SEC on 2015-08-05.
Scheduled sale ($131k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| TCDA | SELL | 2019-09-30 | $132K | — | Filing → |
| TCDA | SELL | 2019-08-28 | $139K | — | Filing → |
| TCDA | SELL | 2019-07-29 | $133K | — | Filing → |